Gspt1 compounds and methods of using the same

CN122422307APending Publication Date: 2026-07-17BRISTOL MYERS SQUIBB CO
View PDF 69 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BRISTOL MYERS SQUIBB CO
Filing Date
2024-10-15
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing cancer treatments have toxicity and side effects, and are difficult to effectively treat relapsed, refractory, or drug-resistant leukemia.

Method used

Compounds of formula I, II, or III, and their pharmaceutically acceptable salts, solvates, hydrates, cocrystals, etc., are provided for the preparation of pharmaceutical compositions, which, in combination with surgery, chemotherapy, radiotherapy, hormone therapy, biological therapy, etc., form combination therapies for the treatment, prevention, or management of cancer, particularly leukemia.

Benefits of technology

Effective treatment, prevention, and management of cancer, including solid tumors and leukemia, with reduced toxicity and side effects, suitable for relapsed, refractory, or drug-resistant leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122422307A_ABST
    Figure CN122422307A_ABST
Patent Text Reader

Abstract

本文提供了用于治疗、预防或管理癌症的式I的化合物及其药学上可接受的盐。还提供了包含所述化合物及其药学上可接受的盐的药物组合物，以及所述化合物、盐和组合物的使用方法。在某些实施方案中，所述方法涵盖治疗、预防或管理癌症，包括实体瘤和血源性肿瘤。
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Medication method

    US3536809A

  • Bandage for administering drugs

    US3598123A

  • Osmatic dispensing device for releasing beneficial agent

    US3845770A

  • Osmotic dispensing device with maximum and minimum sizes for the passageway

    US3916899A

  • Osmotic system having laminar arrangement for programming delivery of active agent

    US4008719A